HALO
Halozyme Therapeutics, Inc.
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Best Biotech Stocks 2026 →
Halozyme Therapeutics (HALO) Stock: Buy, Sell, or Hold?
$101.68
-1.30 (-1.26%)
▼
5d:
-21.99%
30d:
-7.24%
90d:
+1.0%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 05, 2026
0d
Protect HALO Gains
Updated Nov 11, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (56%)
Quality Score
51/100
Position
OVERSOLD
30-Day Fair Range
$108.82 – $128.50
Position: OVERSOLD
Forward P/E & Valuation
9.6x
FAIR
vs 8.5x historical avg
Wall Street Target
$119.89
+17.9% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$99.27 / $134.00
Trend: Strong Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR STABILIZATION: HALO is down 22.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Nov 6, 2026 at $104.53 · last confirmed Nov 10, 2026
Strength: 7.2/10
Get Alerted When HALO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$154.95
Based on 11.6% avg growth
INTRINSIC VALUE TODAY
$96.21
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HALO is currently trading at $101.68, which is considered oversold relative to its 30-day fair value range of $108.82 to $128.50. From a valuation perspective, the stock is trading at a premium (Forward PE: 9.6) compared to its historical average (8.5). At these levels, the market is pricing in 4.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, HALO is in a strong uptrend. The price is currently testing key support at $99.27. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: HALO scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $119.89 (+17.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HALO is in a strong uptrend. The price is currently testing key support at $99.27. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: HALO scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $119.89 (+17.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$108.82 -
$128.50
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
55.7%
Trading Range & Key Levels
30-Day Trading Range
$108.82 -
$128.50
Current vs Trading Range
OVERSOLD
Support Level
$99.27
Resistance Level
$134.00
Current Trend
Strong Uptrend
Technical data as of
Nov 11, 2026
Protect Your Profits
Holding HALO? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (23/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($119.89)
- NEUTRAL: Market pricing in 4.1% annual earnings growth - fairly valued
- WARNING: Composite score 51/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
9.60
Wall Street Target
$119.89
(+17.9%)
Revenue Growth (YoY)
39.2%
Earnings Growth (YoY)
40.6%
Profit Margin
26.9%
Valuation Premium vs History
+4.1% premium
PE vs Historical
9.6 vs 8.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.1%
(market-implied from PE analysis)
1-Year Target
$105.85
(+4%)
2-Year Target
$110.19
(+8%)
3-Year Target
$114.71
(+13%)
3-Yr Target (if PE normalizes)
(PE: 10→9)
PE COMPRESSION
$101.57
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 19.2%)
$356.11
(+250%)
Base:
(SPY PE: 9.6, Growth: 19.2%)
$172.13
(+69%)
Bear:
(PE: 8.2, Growth: 19.2%)
$146.31
(+44%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (26x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 25.75 | Current EPS (TTM): $4.00
Bull Case
$226.56
(+123%)
Analyst growth 100.0%, PE expands to 28.3
Base Case
$205.96
(+103%)
Market implied 100.0%, PE stable at 25.8
Bear Case
$70.03
(-31%)
Severe decline -20.0%, PE contracts to 21.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share HALO Analysis
Share this live HALO analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (HALO)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 7, 2026
Daily AI digest
AI Retail Discussion Summary:
Halozyme Therapeutics (HALO) reported record Q3 2026 revenue and net income, with higher full-year guidance. The stock has seen substantial gains YTD and 1-year total shareholder return, but has slipped recently. The latest earnings have investors debating the stock's fair value.
Key Retail Themes:
Halozyme's record earnings
Investor debate on fair value
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 6:46 PM ET
Data refreshes hourly during market hours. Next update: 7:46 PM
Data refreshes hourly during market hours. Next update: 7:46 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HALO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$145 | 31 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
23 analysts |
$1147 | 35 SELL |
|
BNTX
BioNTech SE |
BUY
21 analysts |
$114 | 62 BUY |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 41 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |
Advanced HALO Option Strategies
Professional options setups generated by AI based on today's HALO price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive HALO Research Pages
